Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eli L Diamond

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Eclinicalmedicine|October 3, 2022
Challenges and positive impact of rare cancer caregiving: A mixed-methods study of caregivers of patients with Erdheim-Chester disease and other histiocytic neoplasmsHannah-Rose Mitchell, Allison J Applebaum, Kathleen A Lynch, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
Blood|March 31, 2026
International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic NeoplasmsGaurav Goyal, Oussama Abla, John K C Chan, et al.
Blood Advances|March 29, 2019
A scale for patient-reported symptom assessment for patients with Erdheim-Chester diseaseEli L Diamond, Anne S Reiner, Justin J Buthorn, et al.
Leukemia|November 8, 2024
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasmsMali Salmon-Divon, Refael Meyuchas, Ofer Shpilberg, et al.
Blood|May 18, 2017
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adultsPaul Milne, Venetia Bigley, Chris M Bacon, et al.
Haematologica|May 25, 2019
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i>Jérôme Razanamahery, Eli L Diamond, Fleur Cohen-Aubart, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Blood|May 4, 2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes diseaseOussama Abla, Eric Jacobsen, Jennifer Picarsic, et al.
Blood Advances|October 24, 2023
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasmsBenjamin H Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Eclinicalmedicine|October 3, 2022
Challenges and positive impact of rare cancer caregiving: A mixed-methods study of caregivers of patients with Erdheim-Chester disease and other histiocytic neoplasmsHannah-Rose Mitchell, Allison J Applebaum, Kathleen A Lynch, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
Blood|March 31, 2026
International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic NeoplasmsGaurav Goyal, Oussama Abla, John K C Chan, et al.
Blood Advances|March 29, 2019
A scale for patient-reported symptom assessment for patients with Erdheim-Chester diseaseEli L Diamond, Anne S Reiner, Justin J Buthorn, et al.
Leukemia|November 8, 2024
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasmsMali Salmon-Divon, Refael Meyuchas, Ofer Shpilberg, et al.
Blood|May 18, 2017
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adultsPaul Milne, Venetia Bigley, Chris M Bacon, et al.
Haematologica|May 25, 2019
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i>Jérôme Razanamahery, Eli L Diamond, Fleur Cohen-Aubart, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Blood|May 4, 2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes diseaseOussama Abla, Eric Jacobsen, Jennifer Picarsic, et al.
Blood Advances|October 24, 2023
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasmsBenjamin H Durham, Oshrat Hershkovitz-Rokah, Omar Abdel-Wahab, et al.
Pageof 13